Protective capacity of a IgM/IgA-enriched polyclonal immunoglobulin-G preparation in endotoxemia

Research in Experimental Medicine

Volumn 198, Issue 6, 1998, Pages 325-339

  Oesser, Steffen ^a   Schulze, Claas ^a   Seifert, Jürgen ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Endotoxemia; Immunoglobulin; IVIG; Sepsis

Indexed keywords

ANTIINFECTIVE AGENT; ENDOTOXIN; IMIPENEM; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 6; LIPOPOLYSACCHARIDE;

ACUTE PHASE RESPONSE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENDOTOXEMIA; ESCHERICHIA COLI; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEAN ARTERIAL PRESSURE; MUSCLE; NONHUMAN; OXYGEN TENSION; PRIORITY JOURNAL; PROPHYLAXIS; TISSUE OXYGENATION;

EID: 0032932197     PISSN: 03009130     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004330050115     Document Type: Article

References (48)

1. Abel FL (1989) Myocardial function in sepsis and endotoxin shock. Am J Physiol 257:1265-1281
2. Apri M, Renneberg J, Andersen H-K, Nielsen B, Larsen SO (1995) Bacteremia at a Danish University Hospital during a twenty-five-year period (1968-1992). Scand J Infect Dis 27:245-251
3. Autenrieth IB, Schwarzkopf A, Ewald JH, Karch H, Lissner R (1995) Bactericidal properties of Campylobacter jejuni-specific IgM antibodies in commercial immunoglobulin preparations. Antimicrob Agents Chemother 39(9): 1965-1969
4. Ayala A, Kisala JM, Felt JA, Perrin MM, Chaudry IH (1992) Does endotoxin tolerance prevent the release of inflammatory monokines (interleukin-1, interleukin-6, or tumor necrosis factor) during sepsis? Arch Surg 127:191-197
5. Baumgartner JD, Glauser MP (1993) Immunotherapy of endotoxemia septicemia. Immunobiology 187:464-477
6. Baumgartner JD, Glauser MP, McCutchan JA, Ziegler EJ, Melle G van, Klauber MR, Vogt M, Muehlen E, Luethy R, Chiolero R, Geroulanos S (1985) Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet 2:59-63
7. 2 assessment. Arch Surg 124:853-855
8. Bone RC (1991) A critical evaluation of new agents for the treatment of sepsis. JAMA 266:1686-1690
9. Brandtzaeg IP, Kierulf P, Gaustad P, Skulberg A, Bruun JN, Halvorsen S, Sørensen E (1988) Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis 159:195-204
10. Burd RS, Battafarano RJ, Cody CS, Farber MS, Ratz CA, Dunn DL (1993) Anti-endotoxin monoclonal antibodies inhibit secretion of tumor necrosis factor-alpha by two distinct mechanisms. Ann Surg 218:250-261
11. Calandra T, Glauser MP, Schellekens J, Verhoef J, et al (1988) Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trail. Infect Dis 158:312-319
12. Caplan ES (1993) Role of immunmodulator therapy in sepsis. Am J Surg 165 [Suppl 2A]:20-24
13. Cross AS, Opal SM (1995) Endotoxin's role in Gram-negative bacterial infection. Curr Opin Infect Dis 8:156-163
14. Damas P, Ledoux D, Nys M, Vrindts Y, DeGroote D, Franchimont P, Lamy M (1992) Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 215:356-362
15. Danner RL, Elin RJ, Hosseini JM, Wesley RA, Reilly JM, Parrillo JE (1991) Endotoxemia in human septic shock. Chest 99:169-175
16. De Maria A (1988) Immunization with rough mutants Salmonella minnesota: initial studies in human subjects. J Infect Dis 158:301-311
17. De Simone C, Delogu G, Corbetta G (1988) Intravenous immunoglobulins in association with antibiotics: a therapeutical trial in septic intensive care unit patients. Crit Care Med 16:23-26
18. Dofferhoff AS, Nijland JH, Vries-Hospers HG de, Mulder PO, Weits J, Bom VJ (1991) Effects of different types of antimicrobial agents on endotoxin release from gram-negative bacteria: an in-vitro and in-vivo study. Scand J Infect Dis 23:745-754
19. Dominioni L, Dionigi R, Zanello M, Chiaranda M, Dionigi R, Acquarolo A, Ballabio A, Sguotti C (1991) Effects of high-dose IgG on survival of surgical patients wth sepsis scores of 20 or greater. Arch Surg 126:236-240
20. 2 be included in the routine monitoring of intensive care unit patients? Crit Care Med 19:141-143
21. Flemming I, Julou-Schaeffer G, Gray GA, Parratt JR, Stoclet JC (1991) Evidence that an L-arginine/nitric oxide dependent elevation of tissue cyclic GMP content is involved in depression of vacular reactivity by endotoxin. Br J Pharmacol 103:1047-1052
22. Garbett ND, Munro CS, Cole PJ (1989) Opsonic activity of a new intravenous immunoglobulin preparation: Pentaglobin compared with Sandoglobin. Clin Exp Immunol 76:8-12
23. Gillis S, Ferm FF, Ou W, Smith KA (1978) T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol 120:2027-2032
24. Greenberg RN, Wilson KM, Kunz AY, Wedel NI, Gorelick KJ (1992) Observations using antiendotoxin antibody (E5) as adjuvant therapy in humans with suspected, serious, gram-negative sepsis. Crit Care Med 20:730-735
25. Greenman RL, Schein RM, Martin MA, Wenzel RP, MacIntyre NR, Emmanuel G, Chmel H, Kohler RB, McCarthy M, Plouffe J, Russell JA, the Xoma Sepsis Study Group (1991) A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 266:1097-1125
26. Iwata M, Shimozato T, Tokiwa H, Tsubura E (1987) Antipyretic activity of a human immunoglobulin preparation for intravenous use in an experimental model of fever in rabbits. Infect Immun 55:547-554
27. Jackson SK, Parton J, Barnes A, Poynton CH, Fegan C (1993) Effect of IgM-enriched intravenous immunoglobulin (Pentaglobin) on endotoxemia and anti-endotoxin antibodies in bone marrow transplantation. Eur J Clin Invest 23:540-545
28. Jesdinsky HJ, Tempel G, Castrup HJ, Seifert J (1987) Cooperative group of additional immunoglobulin therapy in severe bacterial infections: results of a multicenter randomized controlled trial in cases of diffuse fibrinopurulent peritonitis. Klin Wochenschr 67:1132-1138
29. McCabe WR, DeMaria A J, Berberich H, Johns MA (1988) Immunisation with rough mutants of Salmonella minnesota: protective activity of IgM and IgG antibody to the R595(Re chemotype) mutant. J Infect Dis 158:291-300
30. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR the CHESS Trial Study Group (1994) Treatment of septic shock with human nonoclonal antibody HA-1A. Ann Intern Med 121:1-5
31. Mileski WJ (1991) Sepsis - what it is and how to recognize it. Surg Clin North Am 71:749-764
32. Nitsche D, Kriewitz M, Rossberg A, Hamelmann H (1987) The quantitative determination of endotoxin in plasma samples of septic patients with the peritonitis using the chromogenic substrate and its correlation with the clinical course of peritonitis. In: Watson SW (ed) Detection of bacterial endotoxin with Limulus amoebocyte lysate test. AR Liss, New York, pp 417-429
33. Nitsche D, Schulze C, Oesser S, Dalhoff A, Sack M (1996) Impact of different of classes of antimicrobial agents on plasma endotoxin activity. Arch Surg 131:192-199
34. Opal SM, Yu RL Jr (1998) Anitendotoxin strategies for the prevention and treatment of septic shock. New approaches and future directions. Drugs 55(4):497-508
35. Pollack M, Huang AI, Prescott RK, Young LS, Hunter KW, Cruess DF, Tsai CM (1983) Enhanced survival in Pseudomonas aeruginosa septicemia associated with high levels of circulating antibody to Escherichia coli endotoxin core. J Clin Invest 72:1874-1881
36. Poynton CH, Jackson S, Fegan C, Barnes RA, Whittaker JA (1992) Use of IgM enriched intravenous immunoglobulin (Pentaglobin) in bone marrow transplantation. Bone Marrow Transplant 9:451-457
37. Reuben AG, Musher DM, Hamil RJ, Broucke I (1989) Polymicrobial bacteremia: clinical and microbiologic patterns. Rev Infect Dis 11:161-183
38. Rietschel ET, Schade U, Jensen M, Wollenweber HW, Lüderitz O, Greisman SG (1982) Bacterial endotoxins: chemical structure, biological activity and the role in septicaemia. Scand J Infect Dis [Suppl] 31:8-21
39. Rintala E, Pulkki K, Mertsola J, Nevalainen T, Nikoskelainen J (1995) Endotoxin, interleukin-6 and pospholipase-A2 as markers of sepsis in patients with hematological malignancies. Scand J Infect Dis 27:39-43
40. Saladino R, Baldwin G, Alpert G, Parsonnet J, Gillis Z, Thompson C, Siber G, Fleisher G (1992) Effect of a human immunoglobulin preparation for intravenous use in a rabbit model of meningococcal endotoxin-induced shock. Crit Care Med 20:816-822
41. Schedel I, Dreikhausen U, Nentwig B, Höckenschnieder M, Rauthmann D, Balikcioglu S, Coldewey R, Deicher H (1991) Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial. Crit Care Med 19:1104-1113
42. Shimozato T, Iwata M, Tamura N (1990) Suppression of tumor necrosis factor-alpha production by human immunoglobulin preparation for intravenous use. Infect Immun 58:1384-1390
43. Teng NH, Kaplan HS, Hebert JM, Moore C, Douglas H, Wunderlich A, Braude AL (1985) Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. Proc Natl Acad Sci USA 82:1790-1794
44. Trautmann M, Held TK, Susa M, Karajan MA, Wulf A, Cross AS, Marre R (1998) Bacterial lipopolysaccharide (LPS)-specific antibodies in commercial human immunoglobulin preparations: superior antibody content of an IgM-enriched product. Clin Exp Immunol 111:81-90
45. Ulmer AJ, Heine H, Feist W, Kusumoto S, Kusama T, Brade H, Schade U, Rietschel ET, Flad HD (1992) Biological activity of synthetic phosphonooxyethyl analogs of lipid A and lipid A partical structures. Infect Immun 60:3309-3314
46. Werdan K, Pilz G (1996) Supplemental immune globulins in sepsis: a critical appraisal. Clin Exp Immunol 104 [Suppl.1]:83-90
47. Ziegler EJ, McCutchan JA, Fierer J, Glauser MP, Sadoff JC, Douglas H, Braude AL (1982) Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 307:1225-1230
48. Ziegler EJ, Fisher CJ, Sprung CL, Straube RC, Sadoff JC, Foulke GE, Wortel CH, Fink MP, Dellinger RP, Teng NH, Allen IE, Berger HJ, Knatterud GL, LoBuglio AF, Smith CR, et al (1991) Treatment of gram-negative bacteremia and septic shock with HA-1 A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. N Engl J Med 324:429-436